



Markets
/
Stocks
/
nasdaq-nvs
/

Novartis AG

NVS

View Detailed Chart

113.400USD

-0.049-0.04%

Close 04/30, 16:00（ET）Quotes delayed by 15 min

223.98BMarket Cap

18.76P/E TTM



Novartis AG

113.400

-0.049-0.04%

Company

Intraday

30m

Today

-0.04%

5 Days

+2.97%

1 Month

+0.74%

6 Months

+3.18%

Year to Date

+16.53%

1 Year

+16.75%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 10 analysts

HOLD

Current Rating

111.494

Target Price

-1.72%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

162

Total

Median

Average

Company name

Ratings

Analysts

Novartis AG

NVS

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(2)

Buy(8)

Indicators

Sell(1)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

1.176

Buy

RSI(14)

60.687

Neutral

STOCH(KDJ)(9,3,3)

82.073

Neutral

ATR(14)

2.396

Low Volatility

CCI(14)

112.938

Buy

Williams %R

7.387

Overbought

TRIX(12,20)

0.059

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

111.904

Buy

MA10

111.184

Buy

MA20

108.970

Buy

MA50

109.976

Buy

MA100

105.516

Buy

MA200

108.945

Buy

News

NFL signs Novartis as first pharmaceutical partner-source

NEW YORK, March 13 (Reuters) - The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based firm Novartis NOVN.S, a league source told Reuters on Thursday.

ReutersThu, Mar 13

US appeals court lifts pause on generic version of Novartis' Entresto

WASHINGTON, Jan 16 - Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' NOVN.S blockbuster heart-failure drug Entresto after a U.S. appeals court ended a temporary pause on MSN's launch.

ReutersThu, Jan 16

Company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Company codeNVS

CompanyNovartis AG

CEODr. Vasant (Vas) Narasimhan, M.D.

Websitehttps://www.novartis.com/